Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study
Abstrakt
S100 proteins are involved in biological events related to colorectal carcinogenesis. Aim of this prospective study was to assess serum concentration of S100A6, A8, A9 and A11 proteins in patients with colorectal neoplasia.
Eighty-four subjects were enrolled: 20 controls (average risk population with normal findings on colonoscopy; 7 men, 13 women, age 23-74, mean 55 +/- 14), 20 patients with non-advanced colorectal adenoma (non-AA, 10 men, 10 women, age 41-82, mean 62 +/- 11), 22 with advanced colorectal adenoma (AA, 15 men, 7 women, age 49-80, mean 64 +/- 8) and 22 with colorectal cancer (CRC, 12 men, 10 women, age 49-86, mean 69 +/- 10). Peripheral venous blood was obtained.
Serum S100 proteins were investigated by enzyme immunoassay technique. Serum S100A6 was significantly lower in CRC (mean 8530 +/- 4743 ng/L), p = .035 compared to controls (mean 11308 +/- 2968 ng/L).
Serum S100A8 was significantly higher in AA (median 11955 ng/L, IQR 2681-34756 ng/L), p = .009 and in CRC (median 27532 ng/L, IQR 6794-35092 ng/L), p .05. Serum concentration of S100A11 was significantly lower in non-AA (mean 3.5 +/- 2.4 mu g/L), p = .004 and in CRC (mean 3.4 +/- 2.4 mu g/L), p = .002 compared to controls (mean 5.9 +/- 2.5 mu g/L).
Sensitivity and specificity for S100A8 protein in patients with CRC were 94% and 73%; positive predictive value 68% and negative predictive value 95%. Patients with colorectal neoplasia have significantly lower serum S100A6 and S100A11 levels, significantly higher S100A8 and unaltered serum S100A9 levels.